KalVista PharmaceuticalsKALV
About: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Employees: 150
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
327% more call options, than puts
Call options by funds: $5.82M | Put options by funds: $1.36M
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 119 [Q2] → 122 (+3) [Q3]
2% less capital invested
Capital invested by funds: $572M [Q2] → $561M (-$11.2M) [Q3]
3.12% less ownership
Funds ownership: 115.13% [Q2] → 112.01% (-3.12%) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
B of A Securities Tazeen Ahmad 31% 1-year accuracy 9 / 29 met price target | 151%upside $22 | Buy Initiated | 18 Dec 2024 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 128%upside $20 | Buy Reiterated | 6 Dec 2024 |
Needham Serge Belanger 37% 1-year accuracy 46 / 126 met price target | 220%upside $28 | Buy Reiterated | 5 Dec 2024 |
Jones Trading Debanjana Chatterjee 0% 1-year accuracy 0 / 3 met price target | 300%upside $35 | Buy Initiated | 27 Sept 2024 |
Financial journalist opinion
Based on 5 articles about KALV published over the past 30 days